Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Immutep's ph. 3 failure surprises analysts, sinks stock
Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.
James Waldron
Mar 13, 2026 9:53am
BMS taps Microsoft AI network to speed lung cancer diagnosis
Jan 20, 2026 9:45am
GSK inks model deal in $50M bet on Noetik's cancer AI platform
Jan 8, 2026 10:30am
Ose narrows focus to conserve cash at expense of wider pipeline
Dec 9, 2025 9:41am
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial
Dec 8, 2025 7:47am
Nuvalent races to FDA to challenge Pfizer for lung cancer market
Nov 17, 2025 7:45am
